STAT3 and glioblastoma: More recently, Cruickshanks et al. (2018) treated MET inhibitor-resistant GBM cell lines with a combination of MET inhibitors (onartuzumab or crizotinib) and inhibitors to one of the upregulated tumorigenic proteins (mTOR, FGFR1, EGFR, STAT3, and COX-2) in these cells.